AccessibilityHelpAbout Us
Alzex Neuropharma logo

Alzex Neuropharma(OTC) TRRI

Market Cap$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-80%
1 Year-99%
1 Month+0%
$0.00
+0.00%
+0.00Today
Alzex Neuropharma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-10
Alzex Neuropharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-04
1 month+0%USD 0.002026-08-04
3 month-66.67%USD 0.002026-06-08
Year to date+100%USD 0.002025-12-30
1 year-99.44%USD 0.072025-09-05
3 year-99.9%USD 0.402023-09-11
5 year-80%USD 0.002021-09-02
Since inception-100%USD 30,000.302008-07-14

Alzex Neuropharma Financials at a Glance

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$254.12K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

5.42 (High)

Price

$0.00

Volume

50

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.07

Estimated Earnings Date

N/A

TRRI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alzex Neuropharma

Alzex Neuropharma Inc. is a biotechnology company focused on developing innovative therapies for neurological disorders. The company aims to address unmet medical needs through its research and development efforts in neuropharmaceuticals.

Products and Services
  • Development of novel neuropharmaceutical therapies
  • Research initiatives targeting neurological disorders
  • Collaboration with research institutions for drug development
Growth Outlook
  • Potential market expansion in the neuropharmaceutical sector
  • Increased investment in R&D to enhance product pipeline
  • Strategic partnerships may accelerate development timelines
Financial Highlights
  • Recent quarterly net income of -$43,325, showing a reduction in losses
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Cash and cash equivalents increased to $160, reflecting improved liquidity
Alzex Neuropharma Inc. operates in a promising sector with significant growth potential. The focus on neurological disorders positions the company to tap into a market with high demand for effective treatments. The recent financial data indicates a strategic effort to reduce losses while maintaining a robust pipeline for future product development. The increase in cash reserves suggests a commitment to sustaining operations and funding ongoing research initiatives. Overall, Alzex Neuropharma Inc. presents an intriguing opportunity for investors interested in the biotechnology field.
AI Generated • Sep 13, 2026

Industry

Metals and Mining

Sector

Materials

CEO

Robert W. Rosner

Website

trinresinc.com

Headquarters

Las Vegas, NV 89123, US

TRRI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

122.39%

Return on Capital

N/A

Return on Assets

-844.65%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.51M

Volume

50

Avg. Volume

6.127

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$246.85K

EBITDA

-$246.85K

Operating Cash Flow

-$37.94K

Capital Expenditure

$0.00

Free Cash Flow

-$37.94K

Cash & ST Invst.

$160.00

Total Debt

$117.12K

Alzex Neuropharma Performance Analysis

Alzex Neuropharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
Alzex Neuropharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Q22024-06-30N/A
Alzex Neuropharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 0.01N/A
20222022-12-31USD -0.11N/A
Alzex Neuropharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31-89.9%
Q22023-06-3047.0%
Q32023-09-30N/A
Q22024-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$54.55

N/A

Employees

11

N/A

Net Income

-$85.58K

-99.0%

EBITDA

-$83.68K

-804.3%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$160.00

-84.3%

Total Debt

$117.12K

+28.4%

Accounts Receivable

$6.46K

-51.2%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$117.12K

+28.4%

Return on Assets

-8.45%

N/A

Return on Invested Capital

74.97%

N/A

Free Cash Flow

-$3.59K

+94.0%

Operating Cash Flow

-$3.59K

+94.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BKSLFBanks Island Gold Ltd.
$0.00+0.00%
RKTEReflectkote, Inc.
$0.00+0.00%
CNTOCentor Energy, Inc.
$0.00+0.00%
GRENGreensmart Corp
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$102.32+1.18%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$51.10-1.22%
INTCIntel
$97.14-0.05%
NOKNokia
$9.84+1.97%

Questions About TRRI

What is the current price of Alzex Neuropharma?

Alzex Neuropharma is trading at $0.00 per share.

What is the 52-week range for Alzex Neuropharma?

Over the past 52 weeks, Alzex Neuropharma has traded between $0.00 and $0.07.

How much debt does Alzex Neuropharma have?

As of the most recent reporting period, Alzex Neuropharma reported total debt of $91.20K.

How much cash does Alzex Neuropharma have on hand?

Alzex Neuropharma reported $1.02K in cash and cash equivalents in its most recent financial results.

What is Alzex Neuropharma’s dividend yield?

Alzex Neuropharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services